PARACELSIAN INC /DE/
NT 10-Q/A, 1998-02-20
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: CHILDRENS BROADCASTING CORP, 8-K, 1998-02-20
Next: OCULAR SCIENCES INC /DE/, S-1, 1998-02-20





                                   Form 12b-25

                     U.S. SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                  FORM 12b-25        Commission File No. 0-19844
                                                                         -------

                           NOTIFICATION OF LATE FILING

                                  (Check One):

[ ] Form 10-K and 10-KSB [ ]Form 20-F  [ ] Form 11-K  
[X] Form 10-Q and 10-QSB [ ] Form N-SAR

For Period Ended: December 31, 1997

[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR

For the Transition Period Ended: 

- --------------------------------------------------------------------------------

         Nothing in this form shall be  construed  to imply that the  Commission
has verified any information contained herein.

- --------------------------------------------------------------------------------

         If the  notification  relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:

 ................................................................................
 ................................................................................

- --------------------------------------------------------------------------------

PART I - REGISTRANT INFORMATION

- --------------------------------------------------------------------------------


Full name of Registrant                          PARACELSIAN, INC.
                                                 -------------------------------

Former name if applicable                               N/A
                                                 -------------------------------

Address of principal executive office              22 LANGMUIR LABORATORIES
(street and number)                                CORNELL TECHNOLOGY PARK
                                                 -------------------------------

City, State and Zip Code                           ITHICA, NEW YORK  14850
                                                 -------------------------------


                                      - 1 -
<PAGE>
- --------------------------------------------------------------------------------

PART II - RULES 12B-25(b) AND (c)

- --------------------------------------------------------------------------------

If the subject report could not be filed without  unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed.

[X]      (a)  The reasons  described  in  reasonable  detail in Part III of this
form could not be eliminated without unreasonable effort or expense;

[X]      (b)  The subject  annual report on Form 10-K,  Form 20-F,  11-K or Form
N-SAR, or portion thereof will be filed on or before the fifteenth  calendar day
following the prescribed due date; or the subject quarterly report or transition
report on Form  10-Q,  or portion  thereof  will be filed on or before the fifth
calendar day following the prescribed due date; and

[ ]      (c)  The  accountant's  statement  or other  exhibit  required  by Rule
12b-25(c) has been attached if applicable.

- --------------------------------------------------------------------------------

PART III - NARRATIVE

- --------------------------------------------------------------------------------

         Due to changes in senior  management and legal counsel,  the registrant
was unable to prepare its quarterly 10-Q on a timely basis. On January 14, 1998,
Tom  Tachovsky  resigned his position as  President  and acting Chief  Executive
Officer  and Chief  Financial  Officer.  On the same  date,  Bernard  Landes was
appointed as President and Chief Executive  Officer.  The Registrant  expects to
file its Form 10-Q for the three months ended  December 31, 1997 by February 23,
1998, 5 calendar days after February 17, 1998, the due date of such Report.

- --------------------------------------------------------------------------------

PART IV - OTHER INFORMATION

- --------------------------------------------------------------------------------

          (1)  Name and telephone  number of person to contact in regard to this
notification


          Bernard Landes                            607-257-4224
        -----------------                        ------------------
               (Name)                            (Telephone Number)
 
 
         (2)  Have all other  periodic  reports  required  under  section 13 or
15(d) of the  Securities  Exchange  Act of 1934 or section 30 of the  Investment
Company Act of 1940 during the  preceding 12 months or for such  shorter  period
that the  registrant  was  required to file such  report(s)  been filed?  If the
answer is no, identify report(s).

                                                                [X] Yes   [ ] No


                                      - 2 -
<PAGE>

         If  so:  Attach  an  explanation  of  the  anticipated   change,   both
narratively and  quantitatively,  and, if  appropriate,  state the reasons why a
reasonable estimate of the results cannot be made.

                                Paracelsian, Inc.
                         ------------------------------
 
has  caused  this  notification  to be signed on its  behalf by the  undersigned
thereunto duly authorized.


Date   February 17, 1998                    By /s/ Bernard Landes
                                             --------------------------------


          ------------------------------------------------------------

                                    ATTENTION

         Intentional  misstatements  or  omissions  of fact  constitute  Federal
Criminal Violations (See 18 U.S.C. 1001).


          ------------------------------------------------------------


                                      - 3 -



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission